Cite
HARVARD Citation
Bennett, R. et al. (2022). The addition of lopinavir-ritonavir to carfilzomib-based triplets can induce meaningful clinical response in carfilzomib-refractory myeloma patients: a single-center experience. Leukemia & lymphoma. 63 (7), pp. 1738-1741. [Online].